Next Article in Journal
Septic Pulmonary Emboli or Pulmonary Metastasis in a Patient with Diabetes Mellitus?
Previous Article in Journal
Pattern of Response to Bronchial Challenge with Histamine in Patients with Non-Atopic Cough-Variant and Classic Asthma
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessArticle
J. Clin. Med. 2018, 7(7), 175; https://doi.org/10.3390/jcm7070175

Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer

1
Department of Medicine III, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
2
Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
3
Department of Internal Medicine III, University of Kiel, Schittenhelmstrasse 12, 24105 Kiel, Germany
4
Department of Surgery, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
These authors share first authorship.
These authors share senior authorship.
*
Author to whom correspondence should be addressed.
Received: 18 June 2018 / Revised: 4 July 2018 / Accepted: 12 July 2018 / Published: 13 July 2018
View Full-Text   |   Download PDF [1675 KB, uploaded 13 July 2018]   |  

Abstract

The tumor necrosis factor–related weak inducer of apoptosis (TWEAK) belongs to the tumor necrosis factor ligand superfamily, which was shown to play an important role in inflammatory and malignant gastrointestinal diseases, including colitis or colorectal cancer. However, in contrast to other members of the TNF ligand superfamily, its role as a biomarker in pancreatic cancer is currently unknown. We analyzed serum levels of A proliferation-inducing ligand (APRIL) and TWEAK in 134 patients with pancreatic cancer. Results were compared with 50 healthy controls and correlated with clinical data. Intratumoral expression of APRIL and TWEAK in pancreatic cancer was analysed using the datasets made available by the TCGA-LIHC project. APRIL serum levels were significantly elevated in patients with pancreatic cancer compared to healthy controls, which is in line with previous findings. Notably, the diagnostic accuracy of circulating APRIL levels was similar to CA19-9, an established tumor marker for pancreatic cancer. In contrast, serum concentrations of TWEAK were decreased in pancreatic cancer patients. Interestingly, no differences in TWEAK concentrations became apparent between different clinical subgroups of pancreatic cancer. Moreover, within our cohort of patients, TWEAK levels did not correlate with the patients’ prognosis and the diagnostic as well as prognostic potential of TWEAK was lower than CA 19-9, when analyzed in this setting. Finally, using data from the TCGA-LIHC project, we demonstrate that expression levels of TWEAK and APRIL represent prognostic markers for patients’ survival according to Kaplan-Meier curve analyses. TWEAK and APRIL serum concentrations are regulated differently in patients with pancreatic cancer, highlighting diverse roles of variant TNF ligands in this type of cancer. View Full-Text
Keywords: TWEAK; APRIL; TNF; serum; pancreatic cancer; biomarker; prognosis TWEAK; APRIL; TNF; serum; pancreatic cancer; biomarker; prognosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Pombeiro, I.; Loosen, S.H.; Roy, S.; Schueller, F.; Niewenhuisen, L.; Luedde, M.; Vucur, M.; Tacke, F.; Binnebösel, M.; Schoening, W.; Trautwein, C.; Luedde, T.; Neumann, U.P.; Roderburg, C. Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer. J. Clin. Med. 2018, 7, 175.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top